September 15, 2020

Around the nation: AstraZeneca restarts late-stage vaccine trial in U.K.

Daily Briefing

    AstraZeneca said it has resumed Phase 3 clinical trials for its new coronavirus vaccine candidate in the United Kingdom after regulators determined it was safe to do so, in today's bite-sized hospital and health industry news from the Delaware, Virginia, and Washington.

    • Delaware: AstraZeneca on Saturday announced that it has resumed Phase 3 clinical trials for its new coronavirus vaccine candidate in the United Kingdom, after the company paused trials globally to investigate a serious illness that had developed in a trial participant in the U.K. The company said it has restarted its trials after U.K. regulators and independent committees investigated and recommended to the U.K. Medicines & Healthcare products Regulatory Agency that it was safe to do so. However, AstraZeneca said its trials in the United States and other countries remain on hold as the company works with global health authorities to determine whether it is safe to resume its studies worldwide (Loftus, Wall Street Journal, 9/13; Johnson, Washington Post, 9/12).

    • Virginia: The University of Virginia Health System will open a $7 million breast cancer center on Oct. 12. The 18,500-square-foot center will have 32 patient rooms and provide medical oncology, plastic surgery, surgical oncology, and other services. It will also offer 3D breast ultrasound, bone density scanning, cancer survivorship clinics, and more (Vaidya, Becker's Hospital Review, 9/11).

    • Washington: Amazon named Maulik Majmudar as the principle medical officer for its first wellness wearable, a wristband device called Halo. Majmudar, who has served as Amazon's medical officer since August 2018, oversaw the team that developed Halo. Before coming to Amazon, Majmudar spent seven years at Massachusetts General Hospital, where he was the associate director of the hospital's Healthcare Transformation Lab (Dyrda, Becker's Health IT, 9/10).
    X
    Cookies help us improve your website experience. By using our website, you agree to our use of cookies.